Recent Advances in Drug Delivery Systems for Anti-Diabetic Drugs: A Review

ISSN: 1875-5704 (Online)
ISSN: 1567-2018 (Print)


Volume 11, 6 Issues, 2014


Download PDF Flyer




Current Drug Delivery

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 126th of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Istvan Toth
School of Pharmacy,University of Queensland
Brisbane, 4072
Australia


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.248

Recent Advances in Drug Delivery Systems for Anti-Diabetic Drugs: A Review

Author(s): Meenu Grover and Puneet Utreja

Affiliation: Faculty of Pharmaceutical Sciences, PCTE Group of Institutes, Near Baddowal Cantt, Ludhiana- 142021, India.

Abstract

Almost 200 million people worldwide are found to be affected by Diabetes mellitus (DM). DM is a metabolic disorder which occurs due to reduced insulin action and/or insulin secretion in the body. Reduced or inactive insulin results in imbalanced food metabolism. With the progression of disease, pathological changes like nephropathy, retinopathy and cardiovascular complications start occurring in the body. DM is mainly categorized into 2 types: type 1 DM and type 2 DM. Type 1 is generally treated through insulin replacement therapy. Type 2 DM is treated with oral hypoglycemics. Oral hypoglycemics are classified into 5 types: sulfonylureas, biguanides, α-glucosidase inhibitors, meglitinide analogues and thiazolidinediones. Conventional dosage forms of most of these drugs bear some drawbacks such as frequent dosing, short half live, and low bioavailability. Therefore, to alleviate the drawbacks associated with conventional dosage forms, efforts have been made in the area of novel and controlled drug delivery system for oral hypoglycemics. Present review highlights various novel and controlled drug delivery systems that have been investigated by different researchers for achieving sustained and controlled drug delivery of oral hypoglycemics and for overcoming the limitations related with the conventional dosage forms of oral hypoglycemics.

Keywords: Diabetics, Oral hypoglycemics, Conventional therapy, Novel Drug Delivery Systems, Sustained release, Marketed formulations.

Purchase Online Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 11
Issue Number: 4
First Page: 444
Last Page: 457
Page Count: 14
DOI: 10.2174/1567201811666140118225021
Advertisement
12th annual Controlled Release Conference

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science